Townsend Letter Alternative Medicine Magazine



  FREE e-Edition


 EDTA Chelation Therapy


 E-mail List

From the Townsend Letter
October 2014

Stress, Pain and Addiction Affect the HPA, HPG, and HPT Axis: Part 1
by Dalal Akoury, MD
Search this site

Page 1, 2, 3


  1. Øverli Ø, Sørensen C, Pulman KG, et al. Evolutionary background for stress-coping styles: relationships between physiological, behavioral, and cognitive traits in non-mammalian vertebrates. Neurosci Biobehav Rev. 2007;31(3):396–412.
  2. Adinoff B, Junghanns K, Kiefer F, Krishnan-Sarin S. Suppression of the HPA axis stress-response: Implications for relapse. Alcohol Clin Exper Res. 2005;29(7):1351–1355.
  3. Maccari S, Darnaudery M, Morley-Fletcher S, et al. Prenatal stress and long-term consequences: Implications of glucocorticoid hormones. Neurosci Biobehav Rev. 2003;27(1–2)119–127.
  4. Marinelli M, Piazza PV. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci. 2002;16(3):387–394.
  5. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87(3):873–904.
  6. Oswald L, Zandi P, Nestadt G, et al. Relationship between cortisol responses to stress and personality. Neuropsychopharmacology. 2006;31(7):1583–1591.
  7. Sayette MD. Does drinking reduce stress? Alcohol Res Health 1999;223(4):250–255.
  8. Sinha R, Talih M, Malison R, et al. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug-cue-induced cocaine craving states. Psychopharmacology. 2003;170:62–72.
  9. Sorocco KH, Lovallo WR, Vincent AS, et al. Blunted hypothalamic–pituitary–adrenocortical axis responsivity to stress in persons with a family history of alcoholism. Int J Psychophysiol. 2006;59(3):210–217
  10. Spanagel R, Heilig M. Addiction and its brain science. Addiction. 2005;100(12):1813–1822.
  11. Barrot M, Marinelli M, Abrous DN, et al. The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent. Eur J Neurosci. 2000;12:973–979.
  12. Valdez GR, Zorrilla EP, Roberts AJ, et al. Antagonism of corticotrophin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol. 2003;29(2):55–60.
  13. Zorrilla EP, Valdez GR, Weiss F. Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology. 2001;158(4):374–381.
  14. Zorrilla EP, Valdez GR, Nozulak J, et al. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rate. Brain Res. 2002;952(2):188–199.
  15. Wang J, Fang Q, Liu Z, et al. Region-specific effects of brain corticotrophin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in rats. Psychopharmacology. 2006;185(1):19–28.
  16. Boileau I, Assad JM, Pihol RO et al (2003). Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49(4):226–231.
  17. Oswald LM et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology. 2005;30:821–832.
  18. Volkow ND, Wang GJ, Fowler JS, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. Pharmacol Exper Ther.1999;291(1):499–515.
  19. Pruessner JC, Champagne F, Meaney MJ, et al. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C]raclopride. Neuroscience. 2004;24(11):2825–2831.
  20. Oswald et al. 2005. Op cit.
  21. Wand G, Oswald L, McCaul ME, et al. Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress. Neuropsychopharmacology. 2007;32(11):2310–2320.
  22. Barrot et al. Op cit.
  23. Piazza PV, Marinelli M, Rouge-Pont F, et al. Stress, glucocorticoids, and mesencephalic dopaminergic neurons: A pathophysiological chain determining vulnerability to psychostimulant abuse. NIDA Research Monogram. 1996;163:277–299.
  24. Puglisi-Allegra S, Kempf E, Cabib S. Role of genotype in the adaptation of the brain dopamine system to stress. Neurosci Biobehav Rev. 1990;14:523–528.
  25. Henry C, Guegant G, Cador M, et al. Prenatal stress in rats facilitates amphetamine-induced sensitization and induces long-lasting changes in dopamine receptors in the nucleus accumbens. Brain Res. 1995;685:179–186.
  26. Zebrowska-Lupina I, Stelmasiak M, Porowska A. Stress, induced depression of basal motility: effects of antidepressant drugs. Pol J Pharmacol Pharm. 1990;42:97–104.
  27. Sampson D, Willner P, Muscat R. Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacol Berl. 1991;104:491–495.
  28. Zebrowska-Lupina I, Ossowska G, Klenk-Majewska B. The influence of antidepressants on aggressive behavior in stressed rats: the role of dopamine. Pol J Pharmacol Pharm. 1992;44:325–335.
  29. Roth KA, Mefford IM, Barchas JD. Epinephrine, norepinephrine, dopamine and serotonin: differential effects of acute and chronic stress on regional brain amines. Brain Res. 1982;239(2):417–424.
  30. Meiser J, Weindl D, Hiller K . Complex of dopamine metabolism. Cell Commun Signal. 2013;11(1):34.
  31. Volkow ND, Fowler JS, Wang GJ, et. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14(2):169–177.
  32. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999;22:521–527.
  33. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006;30:215–238.
  34. Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci. 2007;8:844–858.
  35. Breiter HC et al. Acute effects of cocaine on human brain activity and emotion. Neuron. 1997;19:591–611.
  36. Martinez D et al. Imaging the neurochemistry of alcohol and substance abuse. Neuroimaging Clin N Am. 2007;17:539–555.
  37. Oswald et al. 2005. Op cit.
  38. Yoder KK et al. Dopamine D2 receptor availability is associated with subjective responses to alcohol. Alcohol Clin Exp Res. 2005;29:965–970.
  39. Rouge-Pont F et al. Individual differences in stress-induced dopamine release in the nucleus accumbens are influenced by corticosterone. Eur J Neurosci. 1998;10:3903–3907.
  40. Barrot et al. Op cit.
  41. Wang B et al. Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: a role in stress-induced relapse to drug seeking. J Neurosci. 2005;25:5389–5396
  42. Wand GS et al. Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress. Neuropsychopharmacology. 2007;32:2310–2320.
  43. Liston C et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci. 2006;26:7870–7874.
  44. Berridge K, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev. 1998;28:309–369.
  45. Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med. 2006;12:559–566.
  46. Vuong C, Van Uum SHM, O'Dell LE, Lufty K, Friedman TC. The effects of opioids and opioid analogs of animal and human endocrine systems. Endocr Rev. 2010;31(1):98–132.
  47. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170–175
  48. Merza Z. Chronic use of opioids and the endocrine system. Horm Metab Res. 2010;42(9):621–623
  49. Van Vugt DA, Baby N, Stewart M, Reid RL (1989). The paradoxical stimulatory effect of morphine on LH secretion is dose-dependent and naloxone-reversible. Neuroendocrinology. 50:109–116.
  50. Del Valle-Soto ME, Iglesias L, Calzada B, Vega JA, Hernandez LC, Pérez-Casas A. Effects of morphine on the pituitary-thyroid axis: morphological and analytical studies. Funct Dev Morphol. 1991;1:3–6.
  51. Orstead KM, Spies HG. Inhibition of hypothalamic gonadotropin-releasing hormone release by endogenous opioid peptides in the female rabbit. Neuroendocrinology. 1987;46:14–23.
  52. Mehmanesh H, Almeida OF, Nikolarakis KE, Herz A. Hypothalamic LH-RH release after acute and chronic treatment with morphine studied in a combined in vivo/in vitro model. Brain Res. 1988;451:69–76.
  53. Li S, Pelletier G. Opioid regulation of gonadotropin-releasing hormone gene expression in the male rat brain as studied by in situ hybridization. Neuroreport. 1993;4:331–333.
  54. Van Vugt DA, Sylvester PW, Aylsworth CF, Meites J. Counteraction of gonadal steroid inhibition of luteinizing hormone release by naloxone. Neuroendocrinology. 1982;34:274–278.
  55. Gabriel SM, Simpkins JW, Kalra SP, Kalra PS. Chronic morphine treatment induces hypersensitivity to testosterone-negative feedback in castrated male rats. Neuroendocrinology. 1985;40:39–44.
  56. Gabriel SM, Berglund LA, Simpkins JW. Chronic morphine treatment enhances the negative and positive feedback effects of estradiol on gonadotropin secretion in ovariectomized rats. Endocrinology. 1987;120:1799–1805.
  57. Ferin M, Vande Wiele R. Endogenous opioid peptides and the control of the menstrual cycle. Eur J Obstet Gynecol Reprod Biol. 1984;18:365–373.
  58. Sirinathsinghji DJ, Motta M, Martini L. Induction of precocious puberty in the female rat after chronic naloxone administration during the neonatal period: the opiate ‘brake' on prepubertal gonadotrophin secretion. J Endocrinol. 1985;104:299–307.
  59. Pende A, Musso NR, Montaldi ML, Pastorino G, Arzese M, Devilla L. Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. Biomed Pharmacother. 1986;40:178–182.
  60. Delitala G, Grossman A, Besser M. Differential effects of opiate peptides and alkaloids on anterior pituitary hormone secretion. Neuroendocrinology. 1983;37:275–279.
  61. Gabriel et al. 1985. Op cit.
  62. Fraioli F, Cappa M, Fabbri A, et al. Lack of endogenous opioid inhibitory tone on LH secretion in early puberty. Clin Endocrinol (Oxf). 1984;20:299–305.
  63. Kletter GB, Padmanabhan V, Beitins IZ, Marshall JC, Kelch RP, Foster CM. Acute effects of estradiol infusion and naloxone on luteinizing hormone secretion in pubertal boys. J Clin Endocrinol Metab. 1997;82:4010–4014.
  64. Mauras N, Rogol AD, Veldhuis JD. Appraising the instantaneous secretory rates of luteinizing hormone and testosterone in response to selective µ opiate receptor blockade in late pubertal boys. J Androl. 1987;8:203–209.
  65. Grossman A. Brain opiates and neuroendocrine function. Clin Endocrinol Metab. 1983;12:725–746.
  66. Devilla L, Pende A, Morgano A, Giusti M, Musso NR, Lotti G. Morphine-induced TSH release in normal and hypothyroid subjects. Neuroendocrinology. 1985;40:303–308.
  67. Ogrin C, Schussler GC. Suppression of thyrotropin by morphine in a severely stressed patient. Endocr J. 2005;52:265–269.
  68. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–2222.
  69. Rasheed A, Tareen IA. Effects of heroin on thyroid function, cortisol and testosterone level in addicts. Pol J Pharmacol. 1995;47:441–444.
  70. Ragni G, De Lauretis L, Bestetti O, Sghedoni D, Gambaro V. Gonadal function in male heroin and methadone addicts. Int J Androl. 1988;11:93–100.
  71. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 3:377–384.
  72. Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006;7:200–210.

Dalal Akoury, MDDalal Akoury, MD, is the founder of AWAREmed Health and Wellness Resource Center and the director of the Wellness U program. Dr. Akoury is board certified in anti-aging, functional, and regenerative medicine, as well as having accumulated more than 20 years of experience in emergency medicine and pediatrics, and a master's degree in public health. Dr. Akoury has also served fellowships in pediatric hematology/oncology and performed research in leukemia and the effects of smoking. This lifetime of experience, along with a unique sensitivity, genuine compassion, and driving passion to inspire health in everyone, has prepared "Dr. Dolly" to be in this place at this time. About developing her dream, AWAREmed and Wellness U, Dr. Akoury says, "My mission is to ignite the spark of health deep within everyone, and to allow this sparkle of wellness to shine through everyone's eyes, becoming one with the universe, and aligning body, mind, and spirit."

Page 1, 2, 3

Consult your doctor before using any of the treatments found within this site.

Subscriptions are available for Townsend Letter, the Examiner of Alternative Medicine
magazine, which is published 10 times each year. Search our pre-2001 archives for further information. Older issues of the printed magazine are also indexed for your convenience.
1983-2001 indices ; recent indices. Once you find the magazines you'd like to order, please
use our convenient form, e-mail, or call 360.385.6021.


Fax: 360.385.0699

Who are we? | New articles | Featured topics | e-Edition |
Tables of contents
| Subscriptions | Contact us | Links | Classifieds | Advertise |
Alternative Medicine Conference Calendar | Search site | Archives |
EDTA Chelation Therapy | Home

© 1983-2014 Townsend Letter
All rights reserved.
Website by Sandy Hershelman Designs